Sign up for updates. Be part of our community.

David King

Advisory Board Member, Atonarp, Inc.

Mr. King has been a director of the Science Center since 2009. He is an experienced lawyer and executive with deep and broad experience in the growth and funding of new entrepreneurial ventures in a number of industries, especially those relating to the life sciences.

Mr. King is currently a member of the Advisory Board of Atonarp, Inc. of Japan, which is using its miniaturized mass spectrometer platform technologies to create unique products for real-time measurements in the natural gas industry, cancer diagnostics and non-invasive blood glucose measurement. From 2008 until his retirement in 2013, Mr. King served as Venture Partner of Quaker Partners, a venture capital firm investing in life science companies. Previously, Mr. King was CEO and founder of BioRexis Pharmaceutical Corporation (acquired by Pfizer), President of Delsys Pharmaceutical Corp. (acquired by Elan), and CEO of Principia Pharmaceutical Corporation (acquired by Human Genome Sciences).

Prior to becoming a successful serial entrepreneur, Mr. King was a partner at Morgan, Lewis & Bockius LLP, an international law firm, where he created and was a leader of the venture capital and emerging business practice. He has served as a director of Cephalon, Inc. (acquired by Teva), 3-Dimensional Pharmaceuticals, Inc. (acquired by Johnson & Johnson), and Morphotek, Inc. (acquired by Eisai). While with Quaker, he served as that fund’s director of Corridor Pharmaceuticals, which is developing novel treatments for pulmonary diseases. He also previously served as executive chair of Diasome Pharmaceuticals (developing orally available forms of insulin), Xencor, Inc. (developing cancer antibody therapeutics), and Inotek Pharmaceuticals (developing drugs for treatment of glaucoma).

Mr. King served on the board of Pennsylvania BIO (now Life Sciences PA) for many years, and was that organization's chair in 2011. In recognition of his contributions to innovation and excellence in the life sciences, he received an honorary doctor of science degree in 2011 from the University of the Sciences. In 2009, he received the Raymond Rafferty Entrepreneurial Excellence Award from the Mid-Atlantic Capital Alliance.

Mr. King received his undergraduate degree from the University of Pennsylvania and his law degree from Harvard Law School.